{
    "organizations": [],
    "uuid": "a64116a2b6282d8950cec260b4b6f72cd5df5ded",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-aclaris-therapeutics-q1-loss-per-s/brief-aclaris-therapeutics-q1-loss-per-share-0-98-idUSASC0A0LP",
    "ord_in_thread": 0,
    "title": "BRIEF-Aclaris Therapeutics Q1 Loss Per Share $0.98",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 8 (Reuters) - Aclaris Therapeutics Inc:\n* ACLARIS THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES UPDATE ON CLINICAL AND COMMERCIAL DEVELOPMENTS\n* Q1 REVENUE $1.1 MILLION VERSUS I/B/E/S VIEW $1 MILLION * QTRLY LOSS PER SHARE $0.98 Source text for Eikon: Further company coverage:\n ",
    "published": "2018-05-09T06:51:00.000+03:00",
    "crawled": "2018-05-09T12:17:03.009+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "aclaris",
        "therapeutic",
        "inc",
        "aclaris",
        "therapeutic",
        "report",
        "first",
        "quarter",
        "financial",
        "result",
        "provides",
        "update",
        "clinical",
        "commercial",
        "development",
        "q1",
        "revenue",
        "million",
        "versus",
        "view",
        "million",
        "qtrly",
        "loss",
        "per",
        "share",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}